08 jun: Det bølgende hus
10 jun: Overskud i APM´s containerforretning
09-06-2012 00:07:00

UPDATE: J&J to Record $600 Million Charge Due to Outstanding Lawsuits

Relateret indhold

--J&J to take litigation charge of about $600 million in second quarter

--Charge deals with litigation surrounding drugs Risperdal, Invega and Natrecor

--Took $1.1 billion litigation charge in the fourth quarter of 2011

(Updated to include details of previous litigation charge in the third paragraph.)

By Ben Fox Rubin

Johnson & Johnson (JNJ) said it plans to record a special charge of roughly $600 million in its second quarter to increase its accrual for potential legal settlements, as it has faced a series of lawsuits over accusations of bribery and improper drug-marketing practices.

The company said the settlement payments stem for a series of outstanding civil cases that involve its drugs Risperdal, Invega and Natrecor, as well as nursing-home pharmacy operator Omnicare Inc. (OCR).

In the fourth quarter, J&J recorded a $1.1 billion charge related to litigation settlements. At the time, Chief Financial Officer Dominic Caruso said the litigation costs were primarily linked to Risperdal. The company didn't have a similar charge in its April first-quarter report.

The health-care products company has faced lawsuits related to alleged off-label promotion of its antipsychotic treatment Risperdal, which was once J&J's top-selling drug before generic copycats hit the market, as well as legal challenges over off-label promotion of another schizophrenia treatment, Invega, and the heart-failure drug Natrecor.

Furthermore, the federal government is suing J&J, accusing it of paying kickbacks to induce Omnicare to encourage use of Risperdal and other J&J drugs.

J&J also has dealt with state lawsuits regarding its promotion of Risperdal, including an Arkansas case in which the company in April was ordered to pay $1.2 billion after a jury found that J&J's past marketing of the drug violated the state's consumer-protection laws. J&J previously was ordered to pay $327 million in a South Carolina case and $258 million in Louisiana. The company is appealing all three cases.

In January, J&J agreed to settle a Texas case for $158 million.

Meanwhile, the company agreed to pay an $85 million fine in a criminal case regarding off-label marketing of Natrecor. Parallel civil litigation still hasn't been settled.

The company in April said its first-quarter earnings rose on a foreign-exchange-related gain tied to an acquisition and lower expenses.

Shares closed Friday at $62.98 and were unchanged after hours. The stock is down 4% so far this year.

--Anjali Athavaley contributed to this report.

Write to Ben Fox Rubin at ben.rubin@dowjones.com

(END) Dow Jones Newswires

June 08, 2012 18:07 ET (22:07 GMT)

Copyright (c) 2012 Dow Jones & Company, Inc.

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
Ingen indlæg

Fondsbørsmeddelelser

Nye digitale betalingsløsninger bryder frem

25-09-2017 08:45:00
Sponsoreret indhold:Af Jens Damgaard, Country Manager, Visa DenmarkEfter 20 år, hvor danskerne har taget imod ganske mange nye løsninger indenfor elektroniske/digitale betalinger, går udviklingen nu endnu hurtigere, og det gør Danmark til et af de mest avancerede betalingsmarkeder i Europa. Avanceret, fordi danskerne er parat til at bruge næsten enhver tænkelig mobil enhed til at betale med.Buti..

Novo: Fiasp godkendt i USA

29-09-2017 16:20:48
De amerikanske sundhedsmyndigheder, FDA, har godkendt Fiasp (hurtigtvirkende insulin aspart), en ny hurtigtvirkende måltidsinsulin, til behandling af voksne med diabetes.Det oplyser Novo Nordisk.FDA's beslutning kommer, efter at kliniske studier har dokumenteret, at Fiasp giver fordele for mennesker, der har behov for en forbedret generel blodsukkerregulering.- Vi er meget glade for, at Fiasp nu o..

Atlantic Petroleum: Direktør fratræder 1. december

29-09-2017 14:02:37
Topchefen for Atlantic Petroleum, der er noteret i Norge og København, direktør Ben Arabo, har opsagt sit job for at tiltræde et andet job på Færøerne.Det oplyser selskabet.Han vil dog blive hos Atlantic Petroleum til 1. december./ritzau/FINANSClaus Mikkelsen +45 33 30 03 35 Ritzau Finans, E-mail: finans@ritzau.dk , www.ritzaufinans.dk

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Vestas sætter gang i første store sol-, vind- og batteriprojekt
2
Novo/Sydbank: Ser aktien stige 3-4 pct. efter positiv anbefaling
3
Aktier/middag: Kun Pandora og Novo undgår sur markedsstemning
4
Novo/ABM: Ventet afgørelse giver den afdæmpede kursreaktion
5
Pandora/Carnegie: Svær september var et lavpunkt - god start på Q4

Relaterede aktiekurser

Johnson & Johnson 142,04 0,0% Aktiekurs uændret

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2017  Disclaimer Privatlivspolitik
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
20. oktober 2017 03:31:12
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20171019.2 - EUROWEB1 - 2017-10-20 03:31:12 - 2017-10-20 03:31:12 - 1 - Website: OKAY